Cerecor Inc. CERC Cash Flow

Cerecor inc. (CERC)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15
Operating activities
Net loss
-21,117	1,621	-4,016	-6,223	-7,454	-5,558	-24,603	-6,007	-3,882	-3,091	18,720	-1,798	-1,960	-1,638	-6,168	-3,524	-5,140	-3,648	-691	-2,912	-3,237
Adjustments to reconcile net loss used in operating activities:
Depreciation and amortization
453	617	1,062	1,104	1,098	1,221	1,070	1,239	1,023	408	5	5	5	-	-	-	-	-	-	-	-
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	6	6	-	6	5	5
Stock-based compensation
1,116	590	818	526	596	634	945	608	242	305	264	255	332	255	287	214	937	73	29	242	50
Acquired in-process research and development, including transaction costs
25,549	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred taxes
20	-12	9	12	5	31	-71	7	15	-832	0	0	0	-	-	-	-	-	-	-	-
Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products
0	-0	67	17	22	38	85	131	45	137	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of Investment in Aytu
7,079	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability and unit purchase option liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-101	90	-47	-	-	-	-
Change in fair value of warrant liability and unit purchase option liability
-11	10	-35	-18	47	-47	2	-3	23	28	-0	-2	3	-	-	-	-	-185	-1,465	-197	535
Change in value of Guarantee
1,800	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-24	-24	246	105	-0	-0	7	13	28	36	45	52	88	112	22	69
Change in fair value of contingent consideration
0	-0	-197	-992	180	-302	84	13	262	0	0	0	0	-	-	-	-	-	-	-	-
Other
0	-	-	-	21	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Accounts receivable, net
695	-3,456	2,095	141	-439	149	-299	477	-104	247	0	0	0	-	-	-	-	-	-	-	-
Grants receivable
-	-	-	-	-	-	-	-	-	-	-45	-112	54	-	-	-	-	-	-	-	-
Other receivables
1,962	140	65	-5,388	62	-795	3,411	32	-371	427	0	0	0	-	-	-	-	-	-	-	-
Inventory, net
-5	68	-148	-411	-41	84	-390	63	554	24	0	0	0	-	-	-	-	-	-	-	-
Grants receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	271	-650	0	-	-	-	-
Prepaid expenses and other assets
-22	776	804	-383	-281	269	291	-389	71	227	-61	152	-141	169	-100	79	-170	-214	-0	241	14
Escrowed cash receivable
-	-	-	-	-	0	-3,757	3	2	1	3,750	0	0	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-63	79	0	0	-	-	-	58
Accounts payable
250	1,639	-619	196	-196	-89	-1,468	-226	1,866	793	-14	-268	-414	222	48	132	-71	-586	321	205	-209
Income taxes payable
-551	-462	-378	-422	-217	-162	24	-95	7	-970	3,230	0	0	-	-	-	-	-	-	-	-
Accrued expenses and other liabilities
-141	-261	-260	-8,387	2,074	1,606	3,788	2,237	160	1,703	563	81	-303	-2,597	1,960	226	291	942	-185	720	-355
Lease liability, net
157	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-5,740	-1,600	-7,700	-6,678	-3,121	-1,975	-538	-333	-280	-2,549	19,123	-1,759	-2,236	-	-	-	-	-	-	-	-
Net cash provided by (used in) operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,433	-3,719	-3,706	-	-1,814	-1,730	-3,069
Investing activities
Net cash paid in merger with Aevi
1,250	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avadel pediatric products acquisition
-	-	-	-	-	0	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Purchase of property and equipment
0	0	5	90	165	499	39	6	19	15	6	0	1	9	6	10	8	-	-	-	-
Net cash used in investing activities
-1,250	-180	-5	-90	-165	-499	1,390	-6	-19	-18,904	-6	0	-1	-	-	-	-	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6	-10	-8	-	-	-	-
Financing activities
Proceeds from exercise of stock options and warrants
74	578	1	162	94	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from registered direct offering, net
5,136	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from shares purchased through employee stock purchase plan
-	-	-	-	-	63	0	-354	363	11	-0	35	0	-	-	-	-	-	-	-	-
Proceeds from sale of shares pursuant to common stock private placement, net
3,887	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from underwritten public offering, net
0	0	0	0	8,975	-	0	0	0	0	0	506	1,186	1,003	1,000	0	0	-	-	-	-
Payment of contingent consideration
0	314	188	150	228	157	137	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment of long-term debt
0	183	24	24	24	0	0	0	0	0	606	892	874	854	836	819	803	-	-	-	-
Payment of offering costs
-	-	-	-	-	-	-	-	-	0	0	88	190	113	-212	173	40	1,493	229	530	15
Net cash provided by financing activities
9,098	135	3,509	97	8,817	6,166	3,838	35	363	11	-606	4,211	120	-	-	-	-	-	-	-	-
Increase in cash, cash equivalents and restricted cash
2,107	-1,725	-4,110	-6,711	5,529	3,691	4,690	-304	63	-	-	-	-	-	-	-	-	-	-	-	-
(Decrease) increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	-	2,452	-2,117	-	-	-	-	-	-	-	-
Supplemental disclosures of cash flow information
Cash paid for interest
0	262	262	262	262	262	262	-44	44	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for taxes
316	477	474	474	378	354	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosures of non-cash activities
Issuance of common stock in Aevi Merger
15,495	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosures of non-cash investing and financing activities
Leased asset obtained in exchange for new operating lease liability
0	0	0	0	743	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	84	17	0	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	26	44	61	79	96	111	133	136	149	149
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	376	-992	-844	-	-1,000	-783	-15
Increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-3,687	-3,064	-4,722	-4,560	17,853	-2,834	-2,514	-3,085